Exelixis, Inc.: stock overview

EXELNASDAQHealthcare · Biological Products, (No Diagnostic Substances)

Price

$69.00

November 13, 2026Market cap $16.8B

DCF calculator

What Ploutos Investor adds for Exelixis

Part of Ploutos Investor, €9.99 a month

See the plans
  • The full history: 17 fiscal years, from 2009
  • The estimated fair value, with its range and its certainty
  • The full analysis, 18 a month
  • More questions to the chat on its filings
  • Excel with every year
  • An email when it reports, changes its dividend or an officer buys

Sign in with a free account to see the last 5 fiscal years.

In short

Exelixis had revenue of $2.5B over the last 12 months and net income of $885M, a net margin of 35.4%. Revenue grew by 18.6% a year on average over the last 5 years. At $69.00 the shares trade at a P/E of 19.0, against a median of 25.4 over the last 5 fiscal years. It holds more cash than debt, by $892M. It pays no dividend.

From its SEC filings (latest fiscal year to January 2, 2026) and the price of November 13, 2026.

Its SEC filings
Market cap
$16.8B
244M shares
P/E
19.0
Today19.0
Median25.4
Revenue, 12 months
$2.5B
+18.6% a year over 5 years
Net margin
35.4%
FY2025: 33.7%, above 94% of its industry

Worth knowing

What a holder would want to hear from the company's SEC filings of the last three years. Each with its filing, without comment.

3 fiscal years in figures

Each fiscal year's figures as the company filed them, and the share price at its end.

FY2023–FY2025 fiscal years

+12.6% a year over 2 years

  • FY2025Jan 2, 202610-K
    Revenue$2.3B
  • FY2024Jan 3, 202510-K
    Revenue$2.2B
  • FY2023Dec 29, 202310-K
    Revenue$1.8B

Fiscal years in figures

EXEL's revenue, profit, cash flow and dividend with each year-end price, from 2009 to FY2022, 14 more fiscal years

Part of Ploutos Investor, €9.99 a month

See the plans

Sign in with a free account to see the last 5 fiscal years.

Key figures

The company's current figures in five groups. Each term is explained behind its ⓘ.

Valuation

Market cap 3-year median: $9.5B
$16.8B
Enterprise value 
$15.9B
P/E 3-year median: 19.3
19.0
EV / EBIT 
15.9
EV / Revenue 
6.4
P/B 3-year median: 4.2
9.2
FCF yield 3-year median: 7.1%
6.9%
Earnings yield 3-year median: 5.2%
5.3%

Profitability

Gross margin 
96.3%
Operating margin 
40.2%
Net margin 3-year median: 24.0%
35.4%
ROIC 
39.9%
ROIC, 5-year average 
15.2%
ROE 
44.5%

Growth

Revenue, yearly change 
+7.0%
EPS, yearly change 
+58.0%
FCF, yearly change 
+30.4%
Revenue, average a year 
+18.6%
EPS, average a year 
+51.3%

The yearly change compares FY2025 with FY2024.

Balance sheet

Cash 
$892M
Total debt 
$162M
Of which operating leases 
$162M
Net cash 
$892M
Net debt / EBITDA 
-0.9x
Interest cover 
–
Current ratio 
3.21

Balance sheet of October 2, 2026.

Returns to shareholders

Dividend yield 
0.00%
Buybacks 
5.63%
Total returned 
5.63%
Shares, yearly change 
-7.2%
Valuation against its own pastEach fiscal year's P/E, P/FCF and P/B beside today's, and the DCF calculator for the company.Valuation

Against its industry

Where its margins and returns stood in fiscal 2025 among the SEC filers of its industry (SIC code 28).

Operating margin

37.6%

Above 96% of the 285 companies in its industry, and 95% of all.

Net margin

33.7%

Above 94% of the 302 companies in its industry, and 94% of all.

ROE

36.2%

Above 91% of the 267 companies in its industry, and 94% of all.

ROA

27.5%

Above 96% of the 313 companies in its industry, and 98% of all.

Revenue growth

7.0%

Above 53% of the 292 companies in its industry, and 52% of all.

From the yearly figures every company files with the SEC, for those with revenue of at least $25 million. The industry is the first two digits of the SIC code.

The company at the SEC

How it is registered and when its fiscal year ends.

Name at the SEC
EXELIXIS, INC.
CIK
939767
Exchange
NASDAQ
Industry (SIC)
2836 · Biological Products, (No Diagnostic Substances)
Fiscal year ends
January 1
Latest annual report
January 2, 2026
Reporting currency
USD
Shares
244M

Other companies: Healthcare

The largest companies of the same sector, each with its own page.

The Healthcare sectorAll companies

The full analysis

What do Exelixis's filings show?

These are Exelixis's figures. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.

  • A fair value range built from the filings
  • Earnings quality, debt and red flags
  • Insider and institutional moves
  • The case for and the case against

Questions about EXEL

Didn't find what you were looking for?

Ask us
What is EXEL's market cap?

Exelixis, Inc.'s market cap is $16.8B, at a price of $69.00 on November 13, 2026 and 244M shares.

What is EXEL's P/E?

EXEL's P/E is 19.0, on earnings per share of $3.34 over the last 12 months. The median over the last 5 fiscal years was 25.4.

How much revenue does EXEL have?

Exelixis had revenue of $2.5B over the last 12 months. Over the last 5 years it changed by +18.6% a year on average.

Does EXEL pay a dividend?

No. Exelixis paid no regular dividend over the last 12 months.

Where do the figures come from?

From Exelixis, Inc.'s SEC filings (10-K and 10-Q) and the share price. They hold no analyst estimates and no score, and they are not a recommendation.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

US stocksThe market today, the sectors, the largest companies and the week's results.The market's sectorsThe 11 sectors side by side: returns, share of the market, median P/E and dividend.Compare stocksTwo companies side by side: price over up to ten years, with and without dividends, and every figure.US dividend stocksEach dividend's yield next to whether the company's cash covers it and whether it was ever cut.

The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.